Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections
Marianna Meschiari, Sara Volpi, Matteo Faltoni, et al.
JAC-Antimicrobial Resistance (2021) Vol. 3, Iss. 4
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
Stamatis Karakonstantis, Maria Rousaki, Evangelos I. Kritsotakis
Antibiotics (2022) Vol. 11, Iss. 6, pp. 723-723
Open Access | Times Cited: 147
Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections
Pranita D. Tamma, Emily L. Heil, Julie Ann Justo, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 135
New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review
Angela Raffaella Losito, Francesca Raffaelli, Paola Del Giacomo, et al.
Antibiotics (2022) Vol. 11, Iss. 5, pp. 579-579
Open Access | Times Cited: 59
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams
Milo Gatti, Federico Pea
Expert Review of Anti-infective Therapy (2023) Vol. 21, Iss. 2, pp. 149-166
Closed Access | Times Cited: 36
Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence
Pierluigi Viale, Christian E. Sandrock, Paula Ramírez, et al.
Annals of Intensive Care (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 29
Treatment of carbapenem-resistantPseudomonas aeruginosainfections: a case for cefiderocol
Rafael Cantón, Yohei Doi, Patricia J. Simner
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 8, pp. 1077-1094
Open Access | Times Cited: 36
Cefiderocol Treatment for Severe Infections due to Difficult-to-Treat-Resistant Non-Fermentative Gram-Negative Bacilli in ICU Patients: A Case Series and Narrative Literature Review
Paul-Henri Wicky, Joséphine Poiraud, M.A. Alves, et al.
Antibiotics (2023) Vol. 12, Iss. 6, pp. 991-991
Open Access | Times Cited: 16
New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections
Roland Nau, Jana Seele, Helmut Eiffert
Antibiotics (2024) Vol. 13, Iss. 1, pp. 58-58
Open Access | Times Cited: 6
Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases
Marianna Meschiari, Antoine Asquier-Khati, Giusy Tiseo, et al.
International Journal of Antimicrobial Agents (2024) Vol. 64, Iss. 1, pp. 107186-107186
Closed Access | Times Cited: 6
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia
Milo Gatti, Maddalena Giannella, Matteo Rinaldi, et al.
Antibiotics (2022) Vol. 11, Iss. 12, pp. 1739-1739
Open Access | Times Cited: 26
Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients
Helen Giamarellou, Ilias Karaiskos
Antibiotics (2022) Vol. 11, Iss. 8, pp. 1009-1009
Open Access | Times Cited: 25
Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence
Pasquale Sansone, Luca Gregorio Giaccari, Francesco Coppolino, et al.
Antibiotics (2022) Vol. 11, Iss. 7, pp. 904-904
Open Access | Times Cited: 23
Tratamiento de las infecciones graves por Pseudomonas aeruginosa multirresistente
E. Díaz Santos, C. Mora Jiménez, L. del Río-Carbajo, et al.
Medicina Intensiva (2022) Vol. 46, Iss. 9, pp. 508-520
Closed Access | Times Cited: 22
Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study
Romaric Larcher, Paul Laffont-Lozes, Claire Roger, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 22
Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria
Shio-Shin Jean, I-Min Liu, Po-Chuen Hsieh, et al.
International Journal of Antimicrobial Agents (2023) Vol. 61, Iss. 5, pp. 106763-106763
Closed Access | Times Cited: 14
Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series
Ángel Marcos‐Fendián, Marta Albanell‐Fernández, Montse Tuset, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 4, pp. 1205-1216
Open Access | Times Cited: 14
Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study
Gabriele Palermo, Alice Annalisa Medaglia, Luca Pipitò, et al.
Antibiotics (2023) Vol. 12, Iss. 4, pp. 746-746
Open Access | Times Cited: 13
Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience
Matteo Piccica, Michele Spinicci, Annarita Botta, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 11, pp. 2752-2761
Open Access | Times Cited: 13
Addressing carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa: the potential of cefiderocol and ceftazidime/avibactam plus aztreonam therapy
M. Montero, Sandra Domene-Ochoa, Núria Prim, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2025)
Open Access
Successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis and purulent ventriculitis using cefiderocol combination therapy: a case report and literature review
Xuan Wang, Qihui Liu, Biwu Wu, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2025)
Closed Access
Using a Difficult-to-treat Resistance Index to Gauge Imbalance between Countries’ Antibiotic Resistance Prevalence and Access to Antibiotics: A Scoping Review and Concept Proposal
Morgan Walker, Emad A. Chishti, Christina Yek, et al.
Clinical Microbiology and Infection (2025)
Closed Access
Cefiderocol for the Treatment of Nosocomial Bloodstream Infections Caused by Stenotrophomonas maltophilia: A Case Series and Literature Review
Antonio Vena, Laura Mezzogori, Nadia Castaldo, et al.
Infectious Diseases and Therapy (2025)
Open Access
Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study
Julián Torre‐Cisneros, Benito Almirante, Carmen Martos, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2025)
Open Access
Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram negative bacilli infections: a case series
Baptiste Hoellinger, Célestine Simand, Katy Jeannot, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 3, pp. 393-395
Open Access | Times Cited: 21
Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis
Wesley D. Kufel, Yasmeen Abouelhassan, Jeffrey M. Steele, et al.
Journal of Antimicrobial Chemotherapy (2022) Vol. 77, Iss. 10, pp. 2737-2741
Closed Access | Times Cited: 20
Page 1 - Next Page

Scroll to top